Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novus Therapeutics Inc (NVUS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 40,001
  • Shares Outstanding, K 9,434
  • Annual Sales, $ 0 K
  • Annual Income, $ -14,070 K
  • 60-Month Beta 3.54
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.36
  • Growth Rate Est. (year over year) +277,600.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.79 +11.87%
on 03/25/19
4.51 -5.99%
on 03/21/19
+0.32 (+8.16%)
since 03/18/19
3-Month
2.26 +87.61%
on 01/22/19
5.21 -18.62%
on 02/27/19
+2.08 (+96.30%)
since 01/18/19
52-Week
1.52 +178.95%
on 12/26/18
8.61 -50.75%
on 06/01/18
-0.67 (-13.65%)
since 04/18/18

Most Recent Stories

More News
Novus Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Clinical Updates

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced...

NVUS : 4.24 (+2.17%)
Novus Therapeutics to Participate in the 8th Annual SVB Leerink Global Healthcare Conference

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced...

NVUS : 4.24 (+2.17%)
Novus Therapeutics Doses First Patients in Phase 2a Trial of OP0201

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced...

NVUS : 4.24 (+2.17%)
Company Profile for Novus Therapeutics, Inc.

Novus Therapeutics, Inc. ("Novus") is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat ("ENT"). Novus has two technologies,...

NVUS : 4.24 (+2.17%)
Novus Therapeutics Doses First Subjects in Phase 1 Pharmacodynamics Study of OP0201

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced...

NVUS : 4.24 (+2.17%)
Novus Therapeutics Doses First Patient with Acute Otitis Media in Phase 1 Study of OP0201

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced...

NVUS : 4.24 (+2.17%)
Novus Therapeutics Reports First Quarter 2018 Financial Results

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced...

NVUS : 4.24 (+2.17%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More Share

Trade NVUS with:

Business Summary

Novus Therapeutics, Inc. is a pharmaceutical company. It focused on the acquisition, development and commercialization of ear, nose and throat products. The company's platform consists of OP-01 Foam Platform and OP-02 Surfactant Program. Novus Therapeutics, Inc., formerly known as Tokai Pharmaceuticals...

See More

Key Turning Points

2nd Resistance Point 4.41
1st Resistance Point 4.33
Last Price 4.24
1st Support Level 4.16
2nd Support Level 4.07

See More

52-Week High 8.61
Fibonacci 61.8% 5.90
Fibonacci 50% 5.06
Last Price 4.24
Fibonacci 38.2% 4.23
52-Week Low 1.52

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar